CW Advisors LLC Grows Stake in Amgen Inc. $AMGN

Key Points

• CW Advisors LLC increased its stake in Amgen Inc. by 5.5%, acquiring a total of 76,963 shares valued at approximately $23.99 million.
• The company reported $6.02 EPS for its latest quarter, exceeding analysts' expectations of $5.28, alongside a revenue of $9.18 billion, up 9.4% year-over-year.
• Amgen announced a quarterly dividend of $2.38 per share, yielding 3.2%, with a dividend payout ratio of 77.84%.

CW Advisors LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,963 shares of the medical research company's stock after purchasing an additional 3,997 shares during the quarter. CW Advisors LLC's holdings in Amgen were worth $23,988,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Continuum Advisory LLC lifted its position in Amgen by 0.7% during the 4th quarter. Continuum Advisory LLC now owns 5,154 shares of the medical research company's stock valued at $1,343,000 after acquiring an additional 35 shares during the period. Octavia Wealth Advisors LLC increased its stake in shares of Amgen by 1.5% during the first quarter. Octavia Wealth Advisors LLC now owns 2,435 shares of the medical research company's stock valued at $759,000 after purchasing an additional 35 shares in the last quarter. Affinity Capital Advisors LLC lifted its holdings in shares of Amgen by 4.5% during the first quarter. Affinity Capital Advisors LLC now owns 861 shares of the medical research company's stock valued at $246,000 after purchasing an additional 37 shares during the last quarter. Accredited Investors Inc. boosted its position in shares of Amgen by 1.7% in the 1st quarter. Accredited Investors Inc. now owns 2,164 shares of the medical research company's stock worth $674,000 after purchasing an additional 37 shares in the last quarter. Finally, Rockline Wealth Management LLC grew its stake in shares of Amgen by 3.2% in the 1st quarter. Rockline Wealth Management LLC now owns 1,240 shares of the medical research company's stock worth $386,000 after buying an additional 38 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Amgen Stock Performance

Shares of NASDAQ:AMGN traded down $2.04 during trading on Friday, hitting $293.72. The company's stock had a trading volume of 1,643,970 shares, compared to its average volume of 2,104,120. The company has a 50-day moving average of $293.43 and a 200-day moving average of $293.17. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The firm has a market cap of $158.13 billion, a price-to-earnings ratio of 24.02, a P/E/G ratio of 2.53 and a beta of 0.49. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $339.17.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.18 billion for the quarter, compared to analysts' expectations of $8.86 billion. During the same quarter last year, the company posted $4.97 EPS. The company's revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Friday, August 22nd. Amgen's payout ratio is currently 77.84%.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares of the company's stock, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the transaction, the senior vice president directly owned 8,162 shares in the company, valued at $2,364,368.16. This represents a 15.52% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.76% of the company's stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of recent research reports. Citigroup lifted their price objective on Amgen from $305.00 to $310.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Erste Group Bank downgraded Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Wall Street Zen cut shares of Amgen from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Royal Bank Of Canada decreased their target price on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Finally, William Blair reissued an "outperform" rating on shares of Amgen in a research report on Tuesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Amgen has a consensus rating of "Hold" and an average target price of $303.76.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.